SILO PHARMA INC (SILO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.29-3.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SILO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Exhibit 99.1 Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules $4 million upfront with up to approximately $7.7 million of potential additional gross…
Stated in a supplied disclosure. Management reported: “The aggregate gross proceeds to the Company from the offering are expected to be approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company.” “The potential additional gross proceeds to the Company from the warrants, if fully exercised on a cash basis, will be approximately $7.7 million.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Exhibit 99.1 Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement SARASOTA, FLA., June 18, 2026, Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopha…
Stated in a supplied disclosure. Management reported: “Exhibit 99.1 Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement SARASOTA, FLA., June 18, 2026, Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).”
Looking ahead, we remain confident about our progress toward a first-in-human clinical trial of our lead drug SPC-15 targeting PTSD and successfully advancing our AI agents platform QwikAgents,” said…
Stated in a supplied disclosure. Management reported: “Looking ahead, we remain confident about our progress toward a first-in-human clinical trial of our lead drug SPC-15 targeting PTSD and successfully advancing our AI agents platform QwikAgents,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.”
Implement a stock repurchase program authorized up to $1 million to manage capital allocation and shareholder value.
Acquire complementary technologies and assets to broaden the company’s biopharmaceutical and AI platform capabilities.
Over the trailing year it converted 0.92x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
24 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.